US Capitol Capsule: SCOTUS not ACA cure-all: drug access remains problematic
This article was originally published in Scrip
Executive Summary
Even though the US Supreme Court last week upheld the tax credit subsidies provision of the Affordable Care Act (ACA), ensuring eligible Americans who enrolled in plans operated by the federal government could keep the benefit, making it more likely they will be able to afford their coverage – and in so doing, ensuring biopharmaceutical makers and others in the healthcare sector retain their millions of new customers – there remains some barriers preventing access to care, including to needed medicines, two large drug trade groups pointed out.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.